| MINIREVIEW |
Departments of Obstetrics and Gynecology,1 Microbiology/Immunology, University of Texas Medical Branch, Galveston, Texas2
| INTRODUCTION |
|---|
|
|
|---|
| Cholesterol biosynthesis. |
|---|
| Cholesterol maintains the integrity of lipid rafts. |
|---|
| Cholesterol is required to maintain the functionality (signaling capacity) of lipid rafts. |
|---|
Further studies convincingly showed that cross-linking of GPI-anchored decay-accelerating factor (DAF; also called CD55) with antibodies results in protein tyrosine phosphorylation and association of two protein tyrosine kinases, p56lck and p59fyn (48). At present, it is accepted that signaling molecules are targeted to cytoplasmic leaflets of lipid rafts by myristoylation or palmitoylation (47).
Treatment of cells in culture with the compound methyl-ß-cyclodextrin (M-ß-CD) results in depletion of cholesterol from the plasma membrane followed by dissociation of proteins from rafts (51). M-ß-CD and other cyclic oligosaccharides named ß-cyclodextrins are able to dissolve lipids in their hydrophobic cores and are very efficient at stimulating the removal of cholesterol from a variety of cells in culture (11). The mechanism that allows cyclodextrins to remove cholesterol from cell membranes is related to their ability to reduce the activation energy for cholesterol efflux. Treatment of cells with cholesterol-sequestering agents such as nystatin and filipin or inhibition of cholesterol biosynthesis with the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) is another approach aimed at manipulating raft constituents that results in dissociating protein from rafts. Treatment with lovastatin followed by cholesterol depletion with M-ß-CD was also used to disrupt raft integrity (21).
| Microorganisms target components of cholesterol-enriched microlipid domains (lipid rafts) as their cellular receptors. |
|---|
5ß1 integrin were also mobilized around adhering Dr-positive E. coli (20). Besides CD55, E. coli bearing the Afa/Dr family of adhesins recognizes CD66e (carcinoembryonic antigen [CEA]) and is able to recruit CEA-related cell adhesion molecules (CEACAM) 1 and 6 to sites of bacterial adherence (4). DAF is also targeted by certain viruses of the family Picornaviridae and has been recognized as the cellular receptor for at least six echovirus serotypes as well as for coxsackieviruses A21, B1, B3, and B5 (3, 29, 56). Cardiovirulent coxsackievirus strain B3 binds to the SCR-2 and SCR-3 domains of DAF, similarly to Afa/Dr adhesins. Coxsackievirus A21 binds to the SCR-1 domain of DAF but also requires intercellular adhesion molecule 1 (ICAM-1) for productive infection (46). E. coli expressing FimH adhesin binds to CD48, a GPI-linked receptor present in the lipid rafts of mast cells (1). Mycobacteria, which bind to a variety of cell surface receptors on macrophages, including complement, mannose, Fc, or scavenger receptors, are also capable of interacting directly with the plasma membrane cholesterol. Rich in glycolipid, the mycobacterial cell wall contains a putative high-affinity cholesterol-binding site. It has been postulated that cholesterol may function as a direct "docking site" for mycobacteria and stabilize their interaction with membranes (36).
Cholesterol appears to be involved in the adhesion process of Helicobacter pylori. This notion came from the observation that H. pylori is consistently found in the mucus close to the intercellular junctions of epithelial cellsthe same sites characterized by high concentrations of cholesterol (17). In addition, H. pylori and other Helicobacter species are capable of accumulating pure cholesterol in the membrane fraction from the culture medium. Proteinase K pretreatment of H. pylori prevented interactions between bacteria and cholesterol. This might suggest that proteinaceous components of the bacterial surface are involved in this process. It remains to be elucidated whether uptake of cholesterol by H. pylori protects the bacteria in the gastric environment.
Cholesterol-rich domains are also targeted by chlamydiae, which are strictly intracellular bacterial pathogens. After binding to HeLa cells, chlamydial elementary bodies remain associated with lipid rafts. It has been postulated that a putative host cell receptor for chlamydiae may reside in lipid rafts or colocalize to lipid rafts following binding of chlamydial ligand (19). A role for GPI-anchored proteins in chlamydial binding has not been demonstrated.
Although cholesterol depletion usually does not affect microbial binding, there are a few exceptions. Plasma membrane cholesterol plays a key role in Leishmania donovani infection by affecting the function of the receptor(s) involved in the nonopsonic attachment of the parasite (38). Depletion of cholesterol from macrophages with M-ß-CD resulted in a significant (
45%) reduction in macrophage-parasite interaction relative to that with untreated control cells. The reduction in binding of the parasite to cholesterol-depleted macrophages can be reversed by replenishment of cholesterol, reinforcing the specific requirement for cholesterol in the infection process. These results show that cholesterol depletion may lead to alterations in the interaction of cholesterol with one or more of the many receptors that have been proposed to have a role in the attachment of the parasite. The early contact of Shigella flexneri with epithelial cells is initiated within lipid rafts by interaction of IpaB, a component of the bacterial type III secretion apparatus, with the mammalian surface protein CD44. Cholesterol depletion and resultant disruption of lipid rafts inhibited this interaction and decreased bacterial binding to the epithelial cells (24). While there is no evidence that cholesterol interacts directly with Leishmania or Shigella, these findings may indicate that membrane cholesterol affects the function of surface receptors targeted by these pathogens. The modulatory role of cholesterol in the function of membrane receptors, such as the oxytocin receptor and the cholecystokinin receptor, has been demonstrated previously (14, 59).
| Cholesterol depletion hampers microbial entry into intracellular compartments. |
|---|
Cholesterol is also required for efficient entry of Chlamydia trachomatis. Binding of chlamydial elementary bodies to lipid rafts may lead to the coalescence of rafts into larger entities and subsequent internalization. Extraction of plasma membrane cholesterol resulted in a slight decrease in the total number of cell-associated chlamydiae and in significant (90%) inhibition of internalized chlamydiae (19).
Studies on phagocytosis of the intracellular pathogen Brucella suis demonstrated that while cholesterol depletion or sequestration significantly decreased nonopsonic phagocytosis, this treatment did not prevent opsonic phagocytosis mediated by the Fc receptor (30). Listeria monocytogenes is a rare example of a gram-positive pathogen that requires cholesterol-dependent lipid domain integrity for entry into nonphagocytic epithelial cells (45). Invasion by Listeria monocytogenes is promoted by interaction of the bacterial invasion proteins internalin and InIB with the surface receptors E-cadherin and hepatocyte growth factor receptor. Cholesterol depletion with M-ß-CD prevents invasion by Listeria.
Lipid rafts are present in the plasma membranes of erythrocytes, terminally differentiated cells, and nonendocytic cells, which are targeted by vacuolar pathogens such as the malaria parasite, Plasmodium falciparum (42). Depletion of cholesterol blocks raft assembly and inhibits the formation of new vacuoles, strongly suggesting that rafts play a critical role in establishing a parasitic vacuole. Cholesterol depletion led to a significant reduction in the number of intracellular Leishmania amastigotes due to decreased binding of parasite promastigotes to cholesterol-depleted macrophages.
Cellular infection with poliovirus (PV) is initiated by binding of the virus capsid to its cellular receptor, CD155. The binding is associated with a conformational transition in the PV capsid, which changes the sedimentation coefficient of the virion from 160S to 135S.
Removal of cholesterol with M-ß-CD resulted in inhibition of PV infection, which was partially compensated for by restoring cholesterol levels in cells. In contrast to nonenveloped viruses such as echovirus 1 and 11 or simian virus 40, poliovirus and poliovirus receptors do not colocalize to lipid rafts. Consequently, the loss of lipid raft integrity does not explain how M-ß-CD inhibits PV entry. However, treatment with M-ß-CD may affect other cholesterol-dependent cellular functions such as membrane fluidity, the electrical properties of ion channels, or cellular signaling pathways. It has been proposed that local recruitment of the PV receptor is required to catalyze the conformational transition from 160S to 135S. This process may be affected by impaired membrane fluidity due to cholesterol depletion. Entry of echovirus 11, which is mediated by interaction with DAF, is also inhibited by the lipid raft disruptors M-ß-CD and nystatin (56).
Overall, microbial pathogens exploit a variety of mechanisms to gain access to intracellular compartments. Plasma membrane cholesterol might play a dual role in microbial internalization as a binding site for microbial pathogens and as an integrating constituent of lipid rafts providing a platform for efficient initiation of signaling cascades. The role and repertoire of signaling molecules recruited to lipid rafts in the process of microbial invasion have been characterized only for a limited number of microorganisms. The Rho family GTPase member Rac1 has recently been shown to play an essential role in the invasion of bladder epithelial cells by FimH-expressing E. coli (28). The invasion of epithelial cells by E. coli expressing Afa/Dr adhesins triggers a signaling pathway(s) involving protein tyrosine kinases, phospholipase C
, phosphatidylinositol 3-kinase, protein kinase C, and Rho GTPase Cdc42, leading to rearrangements of the cytoskeleton and pseudopod elongation (4, 34). The inhibition of invasion of numerous microbial pathogens by cholesterol sequestration or depletion supports the argument that cholesterol is a key molecule involved in the invasion process.
| Lipid raft cholesterol is required for viral assembly and budding and for bacterial escape. |
|---|
| Cellular cholesterol affects the intracellular lifestyle of microbial pathogens. |
|---|
Mycobacteria resist lysosomal delivery, in contrast to normal phagocytosis, in which phagosomal contents are delivered to lysosomes. This inhibition of lysosomal delivery is dependent on processes affected by the mycobacteria. Living mycobacteria, once phagocytosed by macrophages, reside within organelles that contain markers of early, but not of late, endosomal compartments. Recently, a protein termed TACO (tryptophan-aspartate-containing coat protein) was identified in phagosomes containing viable mycobacteria (12). This molecule was not present in phagosomes harboring killed bacilli or in any of the endosomal/lysosomal organelles purified from uninfected cells. TACO prevents maturation into or fusion with lysosomes, allowing the mycobacteria to survive within the phagosome. In uninfected macrophages, TACO molecules are associated with a cortical microtubule network, whereas in macrophages containing viable mycobacteria, TACO relocalizes quickly to phagosomal membranes. The process of TACO incorporation into the phagosomal membrane is cholesterol dependent. Mycobacteria entering macrophages via cholesterol-enriched membrane domains are sequestered in TACO-coated phagosomes, which prevent lysosomal delivery and ensure intracellular survival.
| Interference with cholesterol homeostasis modulates the course of the infectious process. |
|---|
The drugs collectively named statins, which inhibit HMG-CoA reductase in the pathway of cholesterol biosynthesis, were found to decrease intracellular bacterial proliferation (8). Lovastatin at nanomolar concentrations reduced growth of Salmonella serovar Typhimurium 6- to 10-fold in mouse macrophages. Statins were also effective at reducing the proliferation of S. enterica in animals. Mice treated with atorvastatin 7 days prior to intraperitoneal infection contained 65% fewer bacteria in their spleens than untreated controls. This effect does not depend on lowering plasma cholesterol levels, due to very low levels of low-density lipoproteins in rodents. Experiments with the inhibitor 4,4,10ß-trimethyl-trans-decal-3ß-ol, which blocks the conversion of squalene oxide to lanosterol and subsequently inhibits the synthesis of all cellular sterols, demonstrated that biosynthetic sterols are not critical for intracellular growth of S. enterica but rather indicated that bacteria need nonsterol intermediates for intracellular growth. The underlying mechanism of the antibacterial activity of statins remains unclear. It has been postulated that statins may interfere with the modulation of small GTPases, which are frequently exploited by pathogens. The antibacterial effect may also be related to induction of apoptosis in infected cells. Clinical retrospective analysis of bacteremic infections due to gram-negative organisms and Staphylococcus aureus showed significant reductions in overall and attributable mortality in patients taking statins compared with patients not taking statins (26). Although the mechanism of lower mortality remains unclear, it has been postulated that the beneficial effect may be related tothe antiinflammatory activity of HMG-CoA reductase inhibitors.
In recent years, the concept of a "cholesterol connection" in infectious diseases has emerged from studies in the fields of microbiology and cell biology. The level of plasma membrane cholesterol appears to be critical in the regulation of microbial entry, intracellular trafficking, and exit (Table 1; Fig. 1). The feasibility of modulating the transmission or viability of pathogens by local cholesterol depletion or by treatment with HMG-CoA reductase inhibitors offers new perspectives for unconventional therapeutic intervention. Much more effort is needed to understand how interference with cholesterol homeostasis at the local or systemic level affects the host-pathogen interaction.
|
|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Baorto, D. M., Z. Gao, R. Malaviya, M. L. Dustin, A. van der Merwe, D. M. Lublin, and S. N. Abraham. 1997. Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic. Nature 389:636-639.[CrossRef][Medline] |
| 2. | Bavari, S., C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M. J. Aman. 2002. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195:593-602. |
| 3. | Bergelson, J. M., M. Chan, K. R. Solomon, N. F. St John, H. Lin, and R. W. Finberg. 1994. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sci. USA 91:6245-6249. |
| 4. | Berger, C. N., O. Billker, T. F. Meyer, A. L. Servin, and I. Kansau. 2004. Differential recognition of members of the carcinoembryonic antigen family by Afa/Dr adhesins of diffusely adhering Escherichia coli (Afa/Dr DAEC). Mol. Microbiol. 52:963-983.[CrossRef][Medline] |
| 5. | Bloch, K. 1965. The biological synthesis of cholesterol. Science 150:19-28. |
| 6. | Brown, M. S., and J. L. Goldstein. 1976. Receptor-mediated control of cholesterol metabolism. Science 191:150-154. |
| 7. | Brown, M. S., and J. L. Goldstein. 1999. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96:11041-11048. |
| 8. | Catron, D. M., Y. Lange, J. Borensztajn, M. D. Sylvester, B. D. Jones, and K. Haldar. 2004. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect. Immun. 72:1036-1042. |
| 9. | Catron, D. M., M. D. Sylvester, Y. Lange, M. Kadekoppala, B. D. Jones, D. M. Monack, S. Falkow, and K. Haldar. 2002. The Salmonella-containing vacuole is a major site of intracellular cholesterol accumulation and recruits the GPI-anchored protein CD55. Cell. Microbiol. 4:315-328.[CrossRef][Medline] |
| 10. | Chatterjee, S., and S. Mayor. 2001. The GPI-anchor and protein sorting. Cell. Mol. Life Sci. 58:1969-1987.[CrossRef][Medline] |
| 11. | Christian, A. E., M. P. Haynes, M. C. Phillips, and G. H. Rothblat. 1997. Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid Res. 38:2264-2272.[Abstract] |
| 12. | Ferrari, G., H. Langen, M. Naito, and J. Pieters. 1999. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97:435-447.[CrossRef][Medline] |
| 13. | Gilbert, R. J. 2002. Pore-forming toxins. Cell. Mol. Life Sci. 59:832-844.[CrossRef][Medline] |
| 14. | Gimpl, G., K. Burger, and F. Fahrenholz. 1997. Cholesterol as modulator of receptor function. Biochemistry 36:10959-10974.[CrossRef][Medline] |
| 15. | Goluszko, P., R. Selvarangan, V. Popov, T. Pham, J. W. Wen, and J. Singhal. 1999. Decay-accelerating factor and cytoskeleton redistribution pattern in HeLa cells infected with recombinant Escherichia coli strains expressing Dr family of adhesins. Infect. Immun. 67:3989-3997. |
| 16. | Guignot, J., I. Peiffer, M. F. Bernet-Camard, D. M. Lublin, C. Carnoy, S. L. Moseley, and A. L. Servin. 2000. Recruitment of CD55 and CD66e brush border-associated glycosylphosphatidylinositol-anchored proteins by members of the Afa/Dr diffusely adhering family of Escherichia coli that infect the human polarized intestinal Caco-2/TC7 cells. Infect. Immun. 68:3554-3563. |
| 17. | Hessey, S. J., J. Spencer, J. I. Wyatt, G. Sobala, B. J. Rathbone, A. T. Axon, and M. F. Dixon. 1990. Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis. Gut 31:134-138. |
| 18. | Ilangumaran, S., H. T. He, and D. C. Hoessli. 2000. Microdomains in lymphocyte signalling: beyond GPI-anchored proteins. Immunol. Today 21:2-7.[CrossRef][Medline] |
| 19. | Jutras, I., L. Abrami, and A. Dautry-Varsat. 2003. Entry of the lymphogranuloma venereum strain of Chlamydia trachomatis into host cells involves cholesterol-rich membrane domains. Infect. Immun. 71:260-266. |
| 20. | Kansau, I., C. Berger, M. Hospital, R. Amsellem, V. Nicolas, A. L. Servin, and M. F. Bernet-Camard. 2004. Zipper-like internalization of Dr-positive Escherichia coli by epithelial cells is preceded by an adhesin-induced mobilization of raft-associated molecules in the initial step of adhesion. Infect. Immun. 72:3733-3742. |
| 21. | Keller, P., and K. Simons. 1998. Cholesterol is required for surface transport of influenza virus hemagglutinin. J. Cell Biol. 140:1357-1367. |
| 22. | Khanna, K. V., K. J. Whaley, L. Zeitlin, T. R. Moench, K. Mehrazar, R. A. Cone, Z. Liao, J. E. Hildreth, T. E. Hoen, L. Shultz, and R. B. Markham. 2002. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Investig. 109:205-211.[CrossRef][Medline] |
| 23. | Kuraya, M., and T. Fujita. 1998. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55). Int. Immunol. 10:473-480. |
| 24. | Lafont, F., V. N. Tran, K. Hanada, P. Sansonetti, and F. G. van der Goot. 2002. Initial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interaction. EMBO J. 21:4449-4457.[CrossRef][Medline] |
| 25. | Liao, Z., L. M. Cimakasky, R. Hampton, D. H. Nguyen, and J. E. Hildreth. 2001. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retrovir. 17:1009-1019.[CrossRef][Medline] |
| 26. | Liappis, A. P., V. L. Kan, C. G. Rochester, and G. L. Simon. 2001. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis. 33:1352-1357.[CrossRef][Medline] |
| 27. | Manie, S. N., S. Debreyne, S. Vincent, and D. Gerlier. 2000. Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly. J. Virol. 74:305-311. |
| 28. | Martinez, J. J., and S. J. Hultgren. 2002. Requirement of Rho-family GTPases in the invasion of type 1-piliated uropathogenic Escherichia coli. Cell. Microbiol. 4:19-28.[CrossRef][Medline] |
| 29. | Martino, T. A., M. Petric, M. Brown, K. Aitken, C. J. Gauntt, C. D. Richardson, L. H. Chow, and P. P. Liu. 1998. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244:302-314.[CrossRef][Medline] |
| 30. | Naroeni, A., and F. Porte. 2002. Role of cholesterol and the ganglioside GM1 in entry and short-term survival of Brucella suis in murine macrophages. Infect. Immun. 70:1640-1644. |
| 31. | Nguyen, D. H., and J. E. Hildreth. 2000. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74:3264-3272. |
| 32. | Nowicki, B., A. Hart, K. E. Coyne, D. M. Lublin, and S. Nowicki. 1993. Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction. J. Exp. Med. 178:2115-2121. |
| 33. | Nowicki, B., J. Moulds, R. Hull, and S. Hull. 1988. A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect. Immun. 56:1057-1060. |
| 34. | Peiffer, I., A. L. Servin, and M. F. Bernet-Camard. 1998. Piracy of decay-accelerating factor (CD55) signal transduction by the diffusely adhering strain Escherichia coli C1845 promotes cytoskeletal F-actin rearrangements in cultured human intestinal INT407 cells. Infect. Immun. 66:4036-4042. |
| 35. | Peyron, P., C. Bordier, E. N. N'Diaye, and I. Maridonneau-Parini. 2000. Nonopsonic phagocytosis of Mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositol-anchored proteins. J. Immunol. 165:5186-5191. |
| 36. | Pieters, J. 2001. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect. 3:249-255.[CrossRef][Medline] |
| 37. | Pralle, A., P. Keller, E. L. Florin, K. Simons, and J. K. Horber. 2000. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J. Cell Biol. 148:997-1008. |
| 38. | Pucadyil, T. J., P. Tewary, R. Madhubala, and A. Chattopadhyay. 2004. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol. Biochem. Parasitol. 133:145-152.[CrossRef][Medline] |
| 39. | Rietveld, A., and K. Simons. 1998. The differential miscibility of lipids as the basis for the formation of functional membrane rafts. Biochim. Biophys. Acta 1376:467-479.[Medline] |
| 40. | Rodgers, W., and J. Zavzavadjian. 2001. Glycolipid-enriched membrane domains are assembled into membrane patches by associating with the actin cytoskeleton. Exp. Cell Res. 267:173-183.[CrossRef][Medline] |
| 41. | Saifuddin, M., T. Hedayati, J. P. Atkinson, M. H. Holguin, C. J. Parker, and G. T. Spear. 1997. Human immunodeficiency virus type 1 incorporates both glycosylphosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78:1907-1911.[Abstract] |
| 42. | Samuel, B. U., N. Mohandas, T. Harrison, H. McManus, W. Rosse, M. Reid, and K. Haldar. 2001. The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J. Biol. Chem. 276:29319-29329. |
| 43. | Scheiffele, P., A. Rietveld, T. Wilk, and K. Simons. 1999. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J. Biol. Chem. 274:2038-2044. |
| 44. | Selvarangan, R., P. Goluszko, V. Popov, J. Singhal, T. Pham, D. M. Lublin, S. Nowicki, and B. Nowicki. 2000. Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli. Infect. Immun. 68:1391-1399. |
| 45. | Seveau, S., H. Bierne, S. Giroux, M. C. Prevost, and P. Cossart. 2004. Role of lipid rafts in E-cadherin- and HGF-R/Met-mediated entry of Listeria monocytogenes into host cells. J. Cell Biol. 166:743-753. |
| 46. | Shafren, D. R., D. J. Dorahy, R. A. Ingham, G. F. Burns, and R. D. Barry. 1997. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 71:4736-4743.[Abstract] |
| 47. | Shenoy-Scaria, A. M., L. K. Gauen, J. Kwong, A. S. Shaw, and D. M. Lublin. 1993. Palmitylation of an amino-terminal cysteine motif of protein tyrosine kinases p56lck and p59fyn mediates interaction with glycosyl-phosphatidylinositol-anchored proteins. Mol. Cell. Biol. 13:6385-6392. |
| 48. | Shenoy-Scaria, A. M., J. Kwong, T. Fujita, M. W. Olszowy, A. S. Shaw, and D. M. Lublin. 1992. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J. Immunol. 149:3535-3541.[Abstract] |
| 49. | Shin, J. S., Z. Gao, and S. N. Abraham. 1999. Bacteria-host cell interaction mediated by cellular cholesterol/glycolipid-enriched microdomains. Biosci. Rep. 19:421-432.[CrossRef][Medline] |
| 50. | Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387:569-572.[CrossRef][Medline] |
| 51. | Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1:31-39.[CrossRef][Medline] |
| 52. | Simons, M., P. Keller, J. Dichgans, and J. B. Schulz. 2001. Cholesterol and Alzheimer's disease: is there a link? Neurology 57:1089-1093. |
| 53. | Stefanova, I., V. Horejsi, I. J. Ansotegui, W. Knapp, and H. Stockinger. 1991. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 254:1016-1019. |
| 54. | Stella, V. J., and R. A. Rajewski. 1997. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14:556-567.[CrossRef][Medline] |
| 55. | Stokes, C. L., P. B. Weisz, S. K. Williams, and D. A. Lauffenburger. 1990. Inhibition of microvascular endothelial cell migration by beta-cyclodextrin tetradecasulfate and hydrocortisone. Microvasc. Res. 40:279-284.[CrossRef][Medline] |
| 56. | Stuart, A. D., H. E. Eustace, T. A. McKee, and T. D. Brown. 2002. A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts. J. Virol. 76:9307-9322. |
| 57. | Takeda, M., G. P. Leser, C. J. Russell, and R. A. Lamb. 2003. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc. Natl. Acad. Sci. USA 100:14610-14617. |
| 58. | Taraboulos, A., M. Scott, A. Semenov, D. Avrahami, L. Laszlo, and S. B. Prusiner. 1995. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell Biol. 129:121-132. |
| 59. | Vance, D. E., and H. Van den Bosch. 2000. Cholesterol in the year 2000. Biochim. Biophys. Acta 1529:1-8.[Medline] |
| 60. | Varma, R., and S. Mayor. 1998. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 394:798-801.[CrossRef][Medline] |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|